FDA Grants Coredio Breakthrough Designation for AI-Powered Heart Failure Monitoring Platform
Key Insights
Coredio (search)'s Cardiac Performance Simulation Engine (CPSE (search)) received FDA breakthrough device designation for AI-powered heart failure assessment using consumer wearables and standard blood pressure cuffs.
The platform creates a digital twin of patients' cardiovascular systems to monitor four key hemodynamic parameters comparable to cardiac catheterization without invasive procedures.
CPSE (search) addresses the critical post-discharge period when approximately 30% of heart failure patients are readmitted within three months and mortality approaches 10%.
Coredio (search)'s artificial intelligence-powered heart failure monitoring platform has secured breakthrough device designation from the U.S. Food and Drug Administration, marking a significant advancement in remote cardiac care. The California-based digital health company's Cardiac Performance Simulation Engine (CPSE (search)) offers a non-invasive alternative to traditional hemodynamic assessment methods, potentially transforming how clinicians monitor heart failure patients after hospital discharge.
Revolutionary AI-Powered Monitoring Technology
CPSE (search) represents a software-only platform designed to deliver catheterization-comparable hemodynamic assessment using consumer smartwatches and standard blood pressure cuffs in both clinical and home settings under physician supervision. The system identifies abnormal status across four key hemodynamic parameters: left ventricular end-diastolic pressure (LVEDP), central venous pressure (CVP), systemic vascular resistance (SVR), and cardiac index (CI).
The platform operates by creating a "digital twin" of a patient's cardiovascular system through artificial intelligence algorithms. Following an initial personalization step where baseline measurements are obtained using protocols such as electrocardiograms, patients can use wearables and blood pressure cuffs for on-demand hemodynamic status monitoring for clinician review.
"CPSE (search) fuses a physics-based digital twin of the cardiovascular system with advanced AI to noninvasively classify the four hemodynamic parameters central to HF management," said Mehdi Mortazawy, Coredio (search)'s co-founder and chief technology officer.
Addressing Critical Post-Discharge Vulnerability
The breakthrough designation addresses a critical gap in heart failure management during the post-discharge period, widely recognized as the most vulnerable time for patients. Research indicates that approximately 30% of patients hospitalized with heart failure are readmitted within three months of discharge, with mortality during this period approaching 10%.
"Heart failure management has long been limited by the gap between what we can measure in the hospital and what we can reliably understand once patients return home," said Dr. Jagmeet P. Singh of Mass General Brigham (search). "Coredio (search)'s approach, using wearable-derived signals and physics-informed AI to estimate hemodynamic status noninvasively, has the potential to give clinicians a more holistic view of patient cardiac function and enable earlier intervention."
Dr. Farrukh Jafri of White Plains Hospital emphasized the platform's potential impact on transitional care: "At White Plains Hospital, our transitional care program focuses on the critical weeks after discharge, when heart failure patients are most vulnerable and least connected to their care team. What drew us to Coredio (search) is its potential to bring hemodynamic-level data into that gap, without requiring invasive devices or additional clinical visits."
Accelerated Regulatory Pathway
Beyond breakthrough designation, CPSE (search) has been accepted into the FDA's Total Product Life Cycle Advisory Program (TAP), a voluntary pilot by the Center for Devices and Radiological Health designed to accelerate patient access to innovative medical devices. This dual recognition places Coredio (search) on an accelerated, priority path toward 510(k) submission.
"These designations from the FDA reflect the scientific rigour and the urgency of the unmet need in HF management and how Coredio (search) is poised to help cardiology specialists and their patients meet this need in the future," Mortazawy commented.
Market Context and Clinical Impact
Heart failure represents the prevalent cause of hospital admission globally, affecting approximately six million Americans. The condition's prevalence is projected to increase by 46% with direct medical costs reaching $53 billion by 2030. GlobalData analysis reveals that the global patient monitoring market is forecast to reach approximately $25.9 billion in 2035.
Dr. Jennifer Monti of SSM Health (search) highlighted the platform's potential to transform clinical decision-making: "Heart failure management has long been limited by the gap between what we can assess invasively or with imaging tools and what we can see at home. Coredio (search)'s approach, extracting catheterization-comparable hemodynamic data from consumer wearables using physics-based AI, has the potential to close that gap and give clinicians the visibility they need to intervene earlier and make more informed decisions for heart failure patients."
The device-agnostic platform is designed to work with wearables patients already own, potentially reducing barriers to adoption and improving patient compliance with monitoring protocols. This approach represents a significant shift from traditional invasive monitoring methods toward accessible, continuous cardiac assessment in home settings.